ARBs and cancer risk

July 2011
Internal Medicine Alert;7/15/2011 Pharmacology Watch, p2
The article reports that the findings of the meta-analysis conducted by the U.S. Food and Drug Administration (FDA) concerning the possible link between angiotensin receptor blockers (ARBs) and cancer reveal that ARBs are not associated with cancer.


Related Articles

  • FDA gears up for meta-analysis guidance.  // Nature Reviews Drug Discovery;Jan2014, Vol. 13 Issue 1, p9 

    The article discusses the workshop regarding meta-analyses by the U.S. Food and Drug Administration (FDA) held in November 2013.

  • How Well Tested Are the Newest Cancer Drugs? Napoli, Maryann // HealthFacts;Sep2002, Vol. 27 Issue 9, p1 

    Focuses on the basis upon which the U.S. Food and Drug Administration approves cancer drugs.

  • Recently, the Food and... Coorsh, Richard // Consumers' Research Magazine;Jul96, Vol. 79 Issue 7, p6 

    Reports on the US Food and Drug Administration's (FDA) approval for new drugs, taxotere and gemcitabine that would cure cancer. Use of taxotere for breast cancer; Similarity of taxotere to another drug, taxol; Use of gemcitabine to reduce pain and extend the lives of pancreatic cancer patients.

  • FDA Approves Provenge.  // Pharmaceutical Executive;May2010, Vol. 30 Issue 5, p13 

    The article reports that the U.S. Food and Drug Administration has approved the cancer vaccine Provenge from Dendreon for the treatment of late-stage prostate cancer.

  • FDA moves to speed cancer drug approvals. Reynolds, Tom // JNCI: Journal of the National Cancer Institute;4/17/96, Vol. 88 Issue 8, p491 

    Reports on United States President Bill Clinton's announcement of an initiative of the US Food and Drug Administration (FDA) to streamline patient access to new cancer therapies. FDA's expansion of its criteria for accelerated approval of cancer drugs to include partial clinical response as...

  • Mail Hormones.  // Time;7/23/1951, Vol. 58 Issue 4, p37 

    The article reports on a warning from the U.S. Food & Drug Administration (FDA) that ignorant use of testosterone can stimulate cancer.

  • Cancer therapy nears OK. Dickinson, James G. // Medical Marketing & Media;Aug97, Vol. 32 Issue 8, p34 

    Reports on the US Food and Drug Administration advisory committee's approval of the drug Rituxan (rituximab) for cancer therapy.

  • Genetic Tests for Prostate Cancer. Kern, Adam; Partin, Alan W. // Reviews in Urology;2013, Vol. 15 Issue 4, p208 

    The article discusses three new genetic assays for prostate cancer which have been recently approved or seeking approval from the U.S. Food and Drug Administration (FDA).

  • Advaxis granted orphan drug status. Zanki, Tom // njbiz;11/11/2013, Vol. 26 Issue 44, p2 

    The article reports that the U.S. Food and Drug Administration (FDA) granted orphan drug status for ADXS-HPV, the lead drug candidate from biotech company Advaxis Inc. for the treatment of human papillomavirus (HPV)-associated head and neck cancer.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics